Skip to content
Screener

Corcept Therapeutics CORT Q1 2026 earnings

Reported April 30, 2026 · After market close

Revenue$164.9MMiss by $20.9M
EPS-$0.30Miss by $0.16
Revenue estimate$185.8M
EPS estimate-$0.14

Next report

Nov 4, 2026 (in a month)
Revenue estimate$323.9M
EPS estimate$0.81

Financials

Q1 2026

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+22.5%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-427%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-438%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$4.29B-64.4%
Enterprise value$4.19B-65.0%
P/E90.6×+0.6×
P/S5.6×-12.0×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.3pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0×0.0×
Current ratio2.9×-0.2×

FAQ

When did Corcept Therapeutics report Q1 2026 earnings?
Corcept Therapeutics (CORT) reported Q1 2026 earnings on April 30, 2026 after market close.
What were Corcept Therapeutics's Q1 2026 revenue and EPS?
Corcept Therapeutics reported revenue of $164.9M and eps of $-0.30 for Q1 2026.
Did Corcept Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $185.8M by $20.9M. EPS missed the consensus estimate of $-0.14 by $0.16.
How did Corcept Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.9% from $157.2M a year earlier.
Where can I find Corcept Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-028892) and the 10-Q periodic report (0001628280-26-028902) directly on SEC EDGAR. The filing index links above go to sec.gov.